Epithelioid malignant peripheral nerve sheath tumors arising in preexisting schwannomas are extremely rare. We report an unusual example occurring in a patient with multiple schwannomas (schwannomatosis), all but 1 of which showed "neuroblastoma-like" histology. By immunohistochemistry, both the epithelioid malignant peripheral nerve sheath tumor and the schwannomas showed a complete loss of the Smarcb1 protein. Subsequent genetic evaluation revealed the presence of a novel germline mutation in the SMARCB1/INI1 gene in the patient and in 3 of her children, 2 of whom were diagnosed with atypical teratoid/rhabdoid tumors of the brain.
S chwannomas are benign, relatively common, nearly always solitary peripheral nerve sheath neoplasms composed exclusively of Schwann cells. Multiple schwannomas, frequently showing a plexiform growth pattern, occur in both neurofibromatosis type 2 (NF2) and in schwannomatosis. 15 Schwannomatosis, defined by the absence of vestibular schwannomas, the key feature of NF2, is a familial or sporadic syndrome that may be associated with germline mutations of the SMARCB1/ INI1 gene. 1, 16 Although the genetic basis of schwannomatosis remains to be established, an estimated 30% of cases of inherited schwannomatosis may be associated with SMARCB1 mutations. 7 Further, some individuals with germline SMARCB1 mutations show a predisposition to schwannomatosis. 2, 10, 11 Malignant transformation is extremely rare in schwannomas, with fewer than 20 reported cases. 18, 20, 22, 26 Unlike neurofibromas, which most often give rise to conventional spindle cell malignant peripheral nerve sheath tumors, sarcomas arising in schwannomas frequently show an epithelioid morphology, including epithelioid malignant peripheral nerve sheath tumor and epithelioid angiosarcoma. 18, 24, 26 Herein we report a highly unusual example of epithelioid malignant peripheral nerve sheath tumor arising in a patient with schwannomatosis, all but 1 of which showed features of the rare "neuroblastoma-like" variant. Subsequent evaluation showed this patient to be a carrier of a novel germline SMARCB1 mutation. To the best of our knowledge, this is the first report of this kind.
CLINICAL HISTORY
A previously well 31-year-old woman presented with a several-year history of a painless, palpable mass along the lateral aspect of the left lower leg. During her third pregnancy, the mass rapidly enlarged, causing numbness of the left foot and prompting her to seek medical attention. Magnetic resonance imaging (MRI) revealed multiple masses arising from the superficial branch of the common peroneal nerve. The largest mass measured 6.7 cm and demonstrated a heterogeneous internal signal on T1-weighted imaging with mixed areas of isointense and hyperintense signal compared with skeletal muscle (Figs. 1A, B ). More inferiorly in the lower leg were several smaller masses with a more uniform signal hypointense to the skeletal muscle. A needle core biopsy demonstrated features of schwannoma. On the basis of MRI findings, the possibility of schwannomatosis was suggested. Further MRI of the right upper extremity above the elbow demonstrated additional masses associated with the right ulnar nerve (Fig. 1C ). The tumors were subsequently resected in a conservative manner. Cranio-spinal MRI was negative for intracerebral lesions, in particular for vestibular schwannomas. Thus, this patient met the clinicopathologic criteria for schwannomatosis. 1, 16 After the demonstration of a Smarcb1-negative epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma (see Pathologic Findings section), the patient was referred for adjuvant radiation therapy. Further discussion revealed that 6 years earlier, her then 6-month-old son had been found to have a 3.7-cm cerebellar mass, ultimately diagnosed as an atypical teratoid/ rhabdoid tumor, without ancillary Smarcb1 analysis. In light of the mother's diagnosis, this tumor was rereviewed and was shown to be Smarcb1 negative (data not shown). Despite aggressive treatment, including chemoradiation and autologous stem cell transplantation, the child died at 18 months of age.
Given the possibility that this family might harbor a germline SMARCB1 mutation, genetic counseling was initiated. During this process, the patient's younger son presented at 18 months of age with symptoms of raised intracranial pressure and was subsequently found to have 
MATERIALS AND METHODS
Tissues were fixed in buffered 10% formalin, embedded in paraffin, sectioned into 4-mm slices, and stained with hematoxylin and eosin as per routine protocol. Immunohistochemistry was performed at the University of Alberta on deparaffinized, rehydrated tissue sections with antibody-specific antigen retrieval techniques using the Ventana Benchmark XT (Ventana Medical Systems, Tucson, AZ) automated system for detection of the following primary antigens: vimentin (prediluted, Ventana), S100 protein (Dako, Glostrup, Denmark, 1:300), and lowmolecular-weight cytokeratins (CAM5.2; Becton Dickinson, Franklin Lakes, NJ, prediluted). Immunohistochemistry for Smarcb1 was performed at Mayo Clinic (clone 25; 1:40, BD Transduction Laboratories, Franklin Lakes, NJ) using steam heat-induced epitope retrieval and the Dako Envision detection system (Dako Corp., Carpinteria, CA).
Pathologic Findings
Histologic sections of the largest peroneal nerve mass demonstrated in part features of schwannoma, including encapsulation, thick-walled blood vessels, Verocay bodies, and a single small "neuroblastoma-like" rosette ( Figs. 2A,  B ). However, much of this specimen consisted of a clearly malignant-appearing neoplasm with an epithelioid-to-rhabdoid cytomorphology, frequent mitotic activity, and geographic necrosis (Figs. 2C). By immunohistochemistry, both the schwannoma and the sarcomatous component were diffusely positive for S100 protein (Fig. 2D ) and vimentin, characteristic of epithelioid malignant peripheral nerve sheath tumor arising within a schwannoma. Other markers were negative. Because of the partially rhabdoid features of the epithelioid malignant peripheral nerve sheath tumor ( Fig. 2E ), immunohistochemistry for Smarcb1 protein was performed, showing complete loss of expression, with retained expression in adjacent non-neoplastic tissues (Fig. 2F ). The smaller tumors arising from the common peroneal and ulnar nerves demonstrated typical features of "neuroblastoma-like" schwannoma as described, 5 including giant rosette-like structures with a central collagenous core surrounded by amitotic, moderately hyperchromatic "small round blue cells" (Figs. 3A-C) . The neuroblastoma-like schwannomas were similarly positive for S100 protein (Fig. 3D ) and negative for Smarcb1 protein expression ( Fig. 3E ).
Molecular Analysis
Genetic analysis was performed on formalin-fixed tumor tissue derived from both the mother and her older (deceased) son. DNA was isolated using a Qiagen Gentra PureGene kit (Germantown, MD), and the samples were sequenced after polymerase chain reaction amplification and screened for copy number using multiplex ligationdependent probe amplification, according to previously reported methods. 3, 4, 12 Both tumor samples demonstrated a deletion of the long arm of chromosome 22 and a 2 base-pair insertion in exon 3 of the SMARCB1 gene (c.245_246insAT). DNA from the blood sample of the mother was also sequenced for exon 3, and it demonstrated the same 2 base-pair insertion (Fig. 4) . Subsequent testing on blood samples from the mother's parents and her 2 other children (the younger son and his sister) was then carried out. Neither of the mother's parents was found to carry the mutation, suggesting that it was a de novo germline abnormality in the mother and an inherited germline mutation in her children (Fig. 5 ). All 3 of the children were found to be carriers of the mutation. Thus far, the daughter is unaffected and is being regularly screened by MRI imaging of the brain. In addition, blood samples from the mother's brother and sister were analyzed and were found to lack the mutation.
DISCUSSION
Schwannomatosis, defined by the presence of multiple nondermal schwannomas in the absence of vestibular schwannomas or of a known constitutional NF2 mutation, is very rare, having an annual incidence of 0.58 cases/1 million persons. 6 Approximately 20% of cases are familial. 2 The overwhelming majority of previously reported schwannomatosis-associated schwannomas have been benign. 1, 15, 17 However, a very small number of malignant peripheral nerve sheath tumors arising in this clinical setting have recently been reported, including 2 examples (in 14 patients) reported by Gonzalvo et al 6 and 1 other case reported by Hadfield et al. 7 Regrettably, neither of these papers illustrates or describes in detail the pathologic features of these tumors, and it is unclear whether these tumors arose within preexisting schwannomas. Swensen et al 23 have also recently described the familial occurrence of malignant rhabdoid tumors in a family with schwannomatosis and germline duplication of exon 6 of SMARCB1. Several additional families in which a germline mutation in the SMARCB1 gene predisposed carriers to schwannomas or rhabdoid tumors have also recently been described. 4, 5 Only a very small number of malignant peripheral nerve sheath tumors have been previously reported as arising within schwannomas. 18, 26 This phenomenon was first described in detail by Woodruff et al in 1994, 26 who reported 2 cases of malignant peripheral nerve sheath tumors arising in schwannomas and conducted a comprehensive review of all previously reported cases, accepting 7 as bona fide. Interestingly, epithelioid morphology was seen in 7 of 9 (78%) of these tumors; the epithelioid variant accounts for 5% or less of all malignant peripheral nerve sheath tumors. 25 This subject was reinvestigated in 2001 by McMenamin and Fletcher, 18 who reported 4 cases of epithelioid malignant peripheral nerve sheath tumors arising in schwannomas, including 2 new cases and 2 cases previously reported by Nayler et al 20 and Mikami et al. 19 McMenamin and Fletcher 18 also described the presence of small clusters of atypical epithelioid cells within other schwannomas, a phenomenon they termed "epithelioid malignant change." The significance of "epithelioid malignant change" in schwannoma remains to be established. We did not observe this in any of the schwannomas in our case. We are not aware of a previous report that has examined Smarcb1 expression in epithelioid malignant peripheral nerve sheath tumors arising in schwannomas, although loss of Smarcb1 expression has been reported by Hornick et al 9 in 50% of epithelioid malignant peripheral nerve sheath tumors. 9 Sporadic schwannomas show retained expression of Smarcb1, whereas familial schwannomatosis-associated schwannomas show a distinctive pattern of partial or "mosaic" loss. 21 In this case, we observed complete loss of Smarb1 expression in both the epithelioid malignant peripheral nerve sheath tumor and neuroblastoma-like schwannomas, most likely reflecting the presence of both the germline SMARCB1 mutation and a second somatic event.
An additional interesting aspect of this case is the presence of multiple "neuroblastoma-like" schwannomas. Neuroblastoma-like schwannoma, described by Goldblum et al in 1994, 5 is a very rare variant of schwannoma defined by the presence of large, collagenous, rosette-like structures surrounded by small, round, somewhat hyperchromatic Schwann cells with scant cytoplasm. We are not aware of a previous report of multiple neuroblastoma-like schwannomas, nor an association with schwannomatosis.
Finally, this is the first report of a germline SMARCB1 mutation in a patient with an epithelioid malignant peripheral nerve sheath tumor arising within a schwannoma, specifically a 2 base-pair insertion in exon 3 of the SMARCB1 gene (c.245_246insAT). This mutation differs from those SMARCB1 mutations previously reported in 2 cases of malignant extrarenal rhabdoid tumors arising in schwannomatosis, including a large duplication involving exon 6 23 and a point mutation in exon 4. 4 In all 3 cases, Smarcb1 protein expression was lost. Smarcb1, an obligate component of the chromatinremodeling SWI/SNF complex, functions as a tumor suppressor. 8 Thus, mutations in familial SMARCB1associated tumors typically confer biallelic loss of function, with a germline "first hit" of 1 SMARCB1 allele, followed by a somatic "second hit." In this case, FIGURE 4 . A, SMARCB1 exon 3 sequencing on the schwannoma from patient 1 demonstrates a 2 bp insertion (c.245_246insAT). B, SMARCB1 exon 3 sequencing on the rhabdoid tumor from patient 2 demonstrates the same 2 bp insertion as his mother. C, SMARCB1 exon 3 sequencing on the blood from the parents of patient 1 is normal, indicating that patient 1 has a de novo mutation that was inherited by her son. Am J Surg Pathol Volume 36, Number 1, January 2012
Epithelioid MPNST and Neuroblastoma-like Schwannomatosis loss of the long arm of chromosome 22 was present in both the mother and her older (deceased) son, representing the somatic allelic loss. It is unclear how loss of functional Smarcb1 results in tumor formation, although a recent report suggests that loss of functional Smarcb1 results in aberrant signaling through the Hedgehog pathway, leading to tumorigenesis. 13 Individuals with germline SMARCB1 mutations have a variable risk of malignant rhabdoid tumor development. 14 In summary, we have reported an extraordinary case of an epithelioid malignant peripheral nerve sheath tumor arising in a schwannoma, in a patient with "neuroblastoma-like" schwannomatosis and a novel germline mutation in the SMARCB1 gene. Cases such as this may provide insight into the mechanisms underlying the rare phenomenon of malignant transformation in schwannomas, in particular the critical role of SMARCB1. In light of the present report, and on the basis of previous reports of malignancy arising in schwannomatosis, patients with this rare syndrome should be carefully followed up for change in tumor size or imaging characteristics, with the hope that early detection of malignant change may improve clinical outcome. Germline testing of such individuals is also critical, as carriers have a theoretical 50% risk of passing an altered allele to their children. It is clear that the same mutation in the family can predispose to both schwannomas (as in the mother in this family) and to malignant rhabdoid tumors (as seen in her children).
